Baidu
map

JAHA:高敏C反应蛋白与缺血性卒中或短暂性脑缺血发作患者预后之间的关系

2022-07-03 MedSci原创 MedSci原创

缺血性卒中或短暂性脑缺血发作后72小时至8天内检测到的hsCRP水平升高与1年卒中复发风险增加相关。

大量的证据强调了炎症在动脉粥样硬化和心脑血管疾病的病理生理学中的关键作用。大多数既往的研究表明,高敏C反应蛋白(hsCRP)是心血管研究中关注最多的细胞因子之一,在卒中复发中发挥了关键作用。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究的目的是探究hsCRP与卒中发病后预后之间的关系。

在这项预先设定的前瞻性亚研究中,共有9438例测量了hsCRP的急性缺血性卒中或短暂性脑缺血发作患者被纳入。根据发病时间将患者分为3组(<24小时、24-72小时、72小时-8天)。该研究的结局包括1年内卒中复发和合并血管事件,依赖性或死亡定义为1年修改Rankin量表评分为3-6分。研究人员采用Cox比例风险和Logistic回归模型分析hsCRP与不同组预后之间的关系。

24小时内、24-72小时、72-8天三组患者的hsCRP中位水平分别为2.01、1.72和1.72mg/L(P<0.05)。与最低四分位数相比,最高四分位数的患者在72小时内卒中复发风险增加(<24小时:调整后风险比[HR]为1.57[95%CI为1.05-2.35],P=0.03;24-72小时:调整后的HR为1.60[95%CI为1.18-2.17],P=0.003)。在急性卒中治疗分级中进一步调整Org10172试验后相关性有所减弱(<24小时:调整后HR为1.51[95%CI为1.01-2.27];P=0.05;24-72小时:调整后HR为1.55[95%CI为1.14-2.10];P=0.01)。这种关联仅存在于大动脉粥样硬化患者(校正HR为1.68[95%CI为1.06-2.64];P=0.03)。然而,在72小时至8天的hsCRP水平中未发现相关性。此外,24-72小时的hsCRP水平与功能不良结局风险增加相关。

由此可见,缺血性卒中或短暂性脑缺血发作后72小时至8天内检测到的hsCRP水平升高与1年卒中复发风险增加相关。

原始出处:

Yu Wang.et al.Association Between High‐Sensitivity C‐Reactive Protein and Prognosis in Different Periods After Ischemic Stroke or Transient Ischemic Attack.JAHA.2022.https://www.ahajournals.org/doi/10.1161/JAHA.122.025464

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
    2022-07-03 zhaohui6731
  7. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1893520, encodeId=d3d518935209f, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu May 25 05:31:53 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806525, encodeId=716c180652585, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Feb 12 11:31:53 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800861, encodeId=3f96180086154, content=<a href='/topic/show?id=8a3be319614' target=_blank style='color:#2F92EE;'>#短暂性脑缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73196, encryptionId=8a3be319614, topicName=短暂性脑缺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Fri Dec 30 11:31:53 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692285, encodeId=8644169228552, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Jul 23 01:31:53 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764563, encodeId=a8a41e64563bd, content=<a href='/topic/show?id=1612e319263' target=_blank style='color:#2F92EE;'>#短暂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73192, encryptionId=1612e319263, topicName=短暂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b6237741961, createdName=12498ca5m95暂无昵称, createdTime=Mon Oct 17 01:31:53 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268858, encodeId=90341268858d0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289270, encodeId=75b612892e05f, content=<a href='/topic/show?id=cd268500578' target=_blank style='color:#2F92EE;'>#脑缺血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85005, encryptionId=cd268500578, topicName=脑缺血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297864, encodeId=2f9d129e86479, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614820, encodeId=be641614820c9, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Sun Jul 03 06:31:53 CST 2022, time=2022-07-03, status=1, ipAttribution=)]

相关资讯

JAMA:未行手术干预的无症状严重颈动脉狭窄患者5年内发生缺血性卒中风险为4.7%

未接受手术干预的患者5年内患同侧颈动脉相关急性缺血性卒中的估计比率为4.7%

Stroke:让LDL-C“背锅”的残余胆固醇变异性和缺血性卒中发生密切相关!

残余胆固醇,而非LDL-C或许才是引起ASCVD的罪魁祸首。

Stroke:镰刀型细胞贫血年轻人的发生隐匿性脑梗的风险并没有增加

患有SCT的成年人表现出正常的脑血管结构和血流动力学功能。

JNNP:心房颤动患者口服抗凝治疗后缺血性卒中的发病病因、二级预防策略和预后

直接口服抗凝剂(DOAC)或维生素K拮抗剂(VKA)可降低非瓣膜性心房颤动(AF)患者的缺血性卒中风险。然而,尽管在一级和二级预防中每年抗凝治疗的比例分别为0.7%至2.3%,但房颤患者仍有相当大的卒

《柳叶刀》子刊:首次验证!这个模式可大幅降低卒中院前救治延迟

研究结果表明,中风1-2-0的教育模式可以在中国其他地区采用,以改善中风患者预后并减轻患者的疾病负担。

Baidu
map
Baidu
map
Baidu
map